关于 A 股限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） 证券代码：600196 股票简称：复星医药 编号：临 2025-094 上海复星医药（集团）股份有限公司 ●本次回购注销原因： 1 详见2025年4月12日于《中国证券报》《上海证券报》《证券时报》和上海证券 交易所网站（https://www.sse.com.cn）发布的相关公告。 于本次债权申报期间（即自2025年4月12日至2025年5月26日），本公司未收 到相关债权人申报债权以要求提前清偿债务或提供相应担保。 （1）部分首次授予及预留授予激励对象离职； （2）限制性 A 股激励计划设定的 2024 年度业绩考核指标未达标，出现限制 性 A 股激励计划规定的回购注销情形。 ●本次回购注销股份的有关情况 | 回购股份数量 | | | 注销股份数量 | | | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

国浩律师（上海）事务所 关于 上海复星医药（集团）股份有限公司 2022 年限制性 A 股股票激励计划 部分限制性股票回购注销实施情况 的 法律意见书 地址：上海市静安区山西北路 99 号苏河湾中心 MT 25-28 层 邮编：200085 电话：(+86)(21)52341668 传真：(+86)(21)52343320 电子信箱：grandallsh@grandall.com.cn 网址：http://www.grandall.com.cn 二〇二五年五月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于 上海复星医药（集团）股份有限公司 2022 年限制性 A 股股票激励计划 部分限制性股票回购注销实施情况 法律意见书 致：上海复星医药（集团）股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受上海复星医药（集团） 股份有限公司（以下简称"复星医药"或"公司"）的委托，担任复星医药 2022 年限制性 A 股股票激励计划（以下简称"本次激励计划"）的法律顾问。根据 《中华人民共和国公司法》（及其不时修订者，以下简称"《公司法》"）、《中 华人民共和国证券法》（及其不时修订者，以下 ...

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲歐盟孤兒藥資格認定的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 上海复星医药（集团）股份有限公司 中國，上海 2025 年5 月2 6 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-093 上海复星医药（集团）股份有限公司 关于控股子公司药品获欧盟孤儿药资格认定的公告 HLX22 为本集团（即本公司及控股子公司/单位，下同）自 AbClon, Inc.许可引 进、并后续自主研发的新型靶向 HER2 的单克隆抗体，拟用于胃癌和乳腺癌等实体瘤 的治疗。2025 年 3 月，HLX22 用于治疗胃癌（GC）已获美国食品药品监督管理局（FDA） 授予孤儿药资格认定(Orphan-drug Designation)。 截至本公告日期（即 2025 年 5 月 26 日），HLX22 单药用于治疗 HER2 过表达晚 期实体瘤于中国境内（不包括港澳台地区，下同）已完成 I 期临床研究；HLX22 联 合标准治疗（即曲妥珠单抗联合化疗，下同）一线治疗局部晚期或转移性胃食管交 接部癌和胃癌的国际多中心 III 期临床试验正在中国境内、日本及澳大利亚开展， 且该国际多中心 III 期临床试验申请已于美国等国家/地区获许可；HLX22 联合标准 治疗一线治疗 HER2 阳性的局部晚期/转移性胃癌、HLX22 联合标准治疗或联合德曲 妥珠单抗治疗 ...

Core Viewpoint - Fosun Pharma's subsidiary Henlius Europe GmbH has received orphan drug designation from the European Commission for HLX22, a humanized anti-HER2 monoclonal antibody injection for gastric cancer treatment [1] Group 1: Product Development - HLX22 is developed by the company under a license from AbClon, Inc. and is intended for the treatment of solid tumors such as gastric and breast cancer [1] - As of April 2025, the company has invested approximately 310 million yuan in the research and development of HLX22 [1] Group 2: Market Potential - According to IQVIA MIDAS data, the global sales of targeted HER2 monoclonal antibody products are projected to be approximately 9.029 billion USD in 2024 [1] - The orphan drug designation will facilitate HLX22's subsequent research, registration, and commercialization in the European Union by providing policy support [1]

Investment Rating - The industry view is rated as Attractive [7] Core Insights - The report highlights over 70 oral presentations from Chinese scholars at the 2025 ASCO, including 11 late-breaking abstracts, showcasing advancements in various pharmaceutical developments [1] - Sino Biopharma's combination of Benmelstobart (PD-L1) with anlotinib showed superior efficacy in first-line squamous non-small cell lung cancer (sq-NSCLC) with a median progression-free survival (mPFS) of 10.12 months compared to 7.79 months for tislelizumab [2] - CSPC's SYS6010 (EGFR ADC) demonstrated preliminary efficacy in advanced gastrointestinal cancers with mPFS of 5.8 months in gastric cancer patients [3] - Kelun Pharma's sac-TMT (TROP2 ADC) achieved a confirmed overall response rate (ORR) of 59.3% in first-line non-squamous NSCLC [4] - Fosun Pharma's HLX43 (PD-L1 ADC) showed an ORR of 31.3% in late-line solid tumors, with competitive results in NSCLC patients [5] Company Summaries Sino Biopharma - The combination therapy of Benmelstobart and anlotinib is expected to release Phase 3 data for first-line NSCLC and maintenance treatment after radiochemotherapy soon [2] - TQB2102 (HER2 bsAbADC) achieved an ORR of 53.4% in late-line HER2 low-expressing breast cancer [2] CSPC - SYS6010 in combination with SYH2051 showed preliminary efficacy for second-line advanced gastrointestinal cancers, with a G3+ treatment-related adverse event (TRAE) rate of 48% [3] - ALMB-0168 (Cx43 agonist) for relapsed/refractory osteosarcoma showed an ORR of 20% and a disease control rate (DCR) of 90% [10] Kelun Pharma - Sac-TMT demonstrated a 70.7% ORR and a mPFS of 13.4 months in first-line triple-negative breast cancer (TNBC) [11] - In the third-line EGFR-mutant NSCLC setting, sac-TMT achieved a PFS of 6.9 months compared to 2.8 months for docetaxel [11] Fosun Pharma - HLX43's competitive ORR of 38.1% in NSCLC patients during the dose-expansion phase indicates potential for further development [5]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder, Fosun High Technology, which has pledged a total of 711,300,000 shares, accounting for approximately 26.63% of the company's total shares as of May 21, 2025 [1][4]. Summary by Sections Share Pledge Overview - As of May 21, 2025, Fosun High Technology holds 35.99% of the company's total shares, with the pledged shares representing 26.63% of the total shares [1][4]. - The total number of shares held by Fosun High Technology and its concerted actions is 967,812,180 shares, of which 890,278,680 are A shares [1][4]. Details of the Pledge - The pledged shares amount to 30,000,000 A shares, which is 1.12% of the total shares, and the funds from this pledge are intended for debt repayment [1][4]. - The pledge does not involve any major asset restructuring or performance compensation guarantees [1][4]. Cumulative Pledge Situation - As of May 21, 2025, the cumulative pledged shares by Fosun High Technology and its concerted actions total 711,300,000 shares, which is 73.50% of their total holdings [1][4]. - Approximately 47,234,250 shares are expected to mature within the next year, representing 48.81% of the pledged shares and about 17.68% of the company's total shares [1][4]. Financial Health and Management - The controlling shareholder's operations are reported to be normal, with sufficient funds for repayment sourced from various means, including bond issuance and investment returns [1][4]. - The company will closely monitor the progress of the share pledges and fulfill its disclosure obligations as required by law and regulations [1][4].

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 股東部分股份質押的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月2 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 ● 截 至 2025 年 5 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-092 上海复星医药（集团）股份有限公司 关于股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ● 截 至 2025 年 5 月 21 日 收 市 ， 控 股 股 东 复 星 高 科 技 持 有 本 公 司 961,424,455 股股份（其中：A 股 889,890,955 股、H 股 71,533,500 股），约占 截至当日收市本公司股份总数的 35.99%。本次股份质押后，复星高科技累计质 押本公司股份数量为 711,300,000 股（均为 A 股），约占截至当日收市本公司股 份总数的 26.63%。 ● 截至 2025 年 5 月 21 日收市，本公司控股股东复星高科技及其一致行动 人（即复星高科技董监高、复星国际有限公司及其董高<包括本公司实际控制人>， 下同）合计持有本公司 967,812,180 股股份（其中：A 股 890,278,680 股、H 股 77,533,500 股），约占截至当日收市 ...